Lakefront Biotherapeutics (LKFT) vs Schrodinger (SDGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Schrodinger (SDGR) has outperformed Lakefront Biotherapeutics (LKFT) over the past year, gaining 35.4% versus a loss of 14.1%. Over five years, LKFT leads with a -43.9% price change compared with -50.7% for SDGR. Schrodinger is the larger company by market cap ($1.97 billion vs $1.93 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | SDGR |
|---|---|---|
| Share price | $29.51 | $26.39 |
| Market cap | $1.93B | $1.97B |
| 1-day change | -1.63% | -3.30% |
| YTD return | -8.26% | +52.63% |
| 1-year return | -14.11% | +35.37% |
| 5-year return | -43.95% | -50.70% |
| P/E ratio (TTM) | 2.81 | — |
| EPS (TTM) | $10.52 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.24 | $33.78 |
| 52-week low | $25.68 | $10.95 |
| Distance from 52-week high | -18.57% | -21.88% |
| Analyst consensus | hold | none |
| Avg. price target upside | +2.27% | -18.79% |
| Average volume | 267.27K | 1.74M |
| Shares outstanding | 65.48M | 65.64M |
| Employees | 196 | 850 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SDGR has outperformed LKFT by 49.5 percentage points over the past year.
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
LKFT vs SDGR FAQ
Which is bigger, Lakefront Biotherapeutics or Schrodinger?
Schrodinger (SDGR) is larger, with a market capitalization of $1.97B compared with $1.93B for Lakefront Biotherapeutics (LKFT).
Which stock has performed better over the past year, LKFT or SDGR?
SDGR returned +35.37% over the past 12 months, compared with -14.11% for LKFT (price return, excluding dividends). Past performance does not predict future results.
Are Lakefront Biotherapeutics and Schrodinger in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.